Apomorphine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Apomorphine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Apomorphine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
Apomorphine | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Apomorphine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Apomorphine | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Apomorphine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Apomorphine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
Apomorphine | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | |
Apomorphine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Apomorphine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Apomorphine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Apomorphine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
Apomorphine | hsa03010 | Ribosome | 1.03E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | |
Apomorphine | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
Apomorphine | hsa03020 | RNA polymerase | 1.81E-02 | 1 | P24928 | POLR2A | More | |
Apomorphine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Apomorphine | hsa04012 | ErbB signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
Apomorphine | hsa04024 | cAMP signaling pathway | 4.80E-02 | 1 | Q13153 | PAK1 | More | |
Apomorphine | hsa04064 | NF-kappa B signaling pathway | 7.08E-05 | 14 | P10415, Q13489, O00463, Q13546, P14778, Q04759, Q9UDY8, Q13077, Q16548, Q8WV28, Q13315, P24522, P09341, Q9UNE0 | BCL2, BIRC3, TRAF5, RIPK1, IL1R1, PRKCQ, MALT1, TRAF1, BCL2A1, BLNK, ATM, GADD45A, CXCL1, EDAR | More | |
Apomorphine | hsa04071 | Sphingolipid signaling pathway | 7.35E-05 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | |
Apomorphine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | |
Apomorphine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Apomorphine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
Apomorphine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
Apomorphine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Apomorphine | hsa04142 | Lysosome | 3.31E-02 | 3 | P43234, Q9UBR2, P34059 | CTSO, CTSZ, GALNS | More | |
Apomorphine | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | |
Apomorphine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
Apomorphine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
Apomorphine | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
Apomorphine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Apomorphine | hsa04217 | Necroptosis | 1.85E-03 | 7 | P01375, P01568, P48023, Q13489, Q13546, Q14765, Q99878 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, H2AC14 | More | |
Apomorphine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Apomorphine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
Apomorphine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
Apomorphine | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | |
Apomorphine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
Apomorphine | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Apomorphine | hsa04613 | Neutrophil extracellular trap formation | 3.12E-05 | 21 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, P04908, Q6FI13, Q93077, P58876, Q16778, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Apomorphine | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
Apomorphine | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
Apomorphine | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Apomorphine | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Apomorphine | hsa04625 | C-type lectin receptor signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | |
Apomorphine | hsa04630 | JAK-STAT signaling pathway | 1.44E-02 | 4 | P01106, Q09472, P48551, P16871 | MYC, EP300, IFNAR2, IL7R | More | |
Apomorphine | hsa04640 | Hematopoietic cell lineage | 1.75E-03 | 8 | P21926, P20023, P11836, P07766, P09693, P01730, P09564, P16871 | CD9, CR2, MS4A1, CD3E, CD3G, CD4, CD7, IL7R | More | |
Apomorphine | hsa04650 | Natural killer cell mediated cytotoxicity | 4.51E-06 | 11 | P16298, P50591, P01375, P20963, Q02750, Q13153, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, PAK1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
Apomorphine | hsa04657 | IL-17 signaling pathway | 5.71E-04 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | |
Apomorphine | hsa04660 | T cell receptor signaling pathway | 3.61E-02 | 1 | Q13153 | PAK1 | More | |
Apomorphine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Apomorphine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Apomorphine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Apomorphine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Apomorphine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
Apomorphine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
Apomorphine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Apomorphine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Apomorphine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
Apomorphine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
Apomorphine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
Apomorphine | hsa04919 | Thyroid hormone signaling pathway | 4.44E-02 | 3 | P60709, Q09472, P01106 | ACTB, EP300, MYC | More | |
Apomorphine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
Apomorphine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
Apomorphine | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
Apomorphine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
Apomorphine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Apomorphine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Apomorphine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
Apomorphine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Apomorphine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Apomorphine | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
Apomorphine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
Apomorphine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Apomorphine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Apomorphine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Apomorphine | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
Apomorphine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.10E-03 | 5 | Q16539, Q13153, P09341, P25024, P25025 | MAPK14, PAK1, CXCL1, CXCR1, CXCR2 | More | |
Apomorphine | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | |
Apomorphine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
Apomorphine | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | |
Apomorphine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
Apomorphine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
Apomorphine | hsa05146 | Amoebiasis | 3.33E-03 | 9 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB | More | |
Apomorphine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Apomorphine | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | |
Apomorphine | hsa05164 | Influenza A | 8.62E-03 | 4 | Q09472, P48551, P29728, P60709 | EP300, IFNAR2, OAS2, ACTB | More | |
Apomorphine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
Apomorphine | hsa05169 | Epstein-Barr virus infection | 1.42E-02 | 5 | P20023, P01106, P48551, P29728, P09693 | CR2, MYC, IFNAR2, OAS2, CD3G | More | |
Apomorphine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
Apomorphine | hsa05171 | Coronavirus disease - COVID-19 | 1.93E-02 | 4 | P48551, P29728, P46777, P50914 | IFNAR2, OAS2, RPL5, RPL14 | More | |
Apomorphine | hsa05202 | Transcriptional misregulation in cancer | 1.08E-04 | 19 | Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, P11215, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, ITGAM, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | |
Apomorphine | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
Apomorphine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Apomorphine | hsa05211 | Renal cell carcinoma | 3.42E-03 | 3 | Q09472, Q99814, Q13153 | EP300, EPAS1, PAK1 | More | |
Apomorphine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
Apomorphine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Apomorphine | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | |
Apomorphine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Apomorphine | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | |
Apomorphine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
Apomorphine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.94E-03 | 8 | O95267, P07766, P09693, P06239, O60603, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD3G, LCK, TLR2, MAPK14, EML4, CD4 | More | |
Apomorphine | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
Apomorphine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
Apomorphine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Apomorphine | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
Apomorphine | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
Apomorphine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
Apomorphine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
Apomorphine | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |